Latham & Watkins Advises IDEAYA in Strategic Partnership with GSK

A Bay Area team advised the oncology-focused precision medicine company.

June 22, 2020

IDEAYA Biosciences, Inc. and GlaxoSmithKline plc (GSK) have announced a strategic partnership in Synthetic Lethality, an emerging field in Oncology. The strategic partnership includes IDEAYA's Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years. IDEAYA will receive a $100 million upfront cash payment, and $20 million equity purchase of IDEAYA common stock in a direct private placement, and a potential $50 million cash option exercise fee for the MAT2A program. 

Latham & Watkins LLP represents IDEAYA Biosciences, Inc. in the transaction. The licensing team was led by Bay Area partner Christopher Hazuka with associate Gavin Liu. The corporate team was led by Bay Area partner Mark Roeder with associate Alexander White. Advice was also provided on antitrust matters by Bay Area partner Joshua Holian with Washington, D.C. counsel Patrick English.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.